Microsoft word - kauffman_towhj
The Open Women’ Health Journal, 2007, 1, 1-3 1
Prolonged Post-Treatment Genital Anesthesia and Sexual Dysfunction
Following Discontinuation of Citalopram and the Atypical Antidepressant
Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center, School of Medicine, 1400 Coulter Drive, Amarillo, Texas 79106 USA
SSRI therapy is commonly associated with sexual side effects, but it is assumed that these distressing symp-
toms resolve with termination of therapy. The atypical antidepressant nefazodone is infrequently associated with sexual
dysfunction and may be substituted for SSRI’s when sexual symptoms are intolerable. Recently, scattered case reports of
persistent sexual dysfunction and genital anesthesia persisting well after termination of SSRI antidepressant therapy have
surfaced. In each case, the underlying depressive disorder was in remission.
Case: A 32-year old women with major depression was treated with citalopram but switched to nefazodone after 4 weeks of therapy due to genital anesthesia and orgasmic dysfunction. These symptoms continued following institution of nefa-zodone therapy and have persisted for over a year since termination of antidepressant treatment. Her depression remains in full remission.
Discussion: It is likely that persistent post-treatment genital anesthesia and other sexual side effects are underreported, and physicians should be aware of this bothersome phenomenon. Formal post-treatment surveillance for this condition is war-ranted. Pharmacogenomic research may ultimately allow physicians to predict who is at risk for antidepressant induced sexual side effects.
Citalopram, SSRI, nefazodone, sexual dysfunction, genital anesthesia.
It is expected that sexual functioning rapidly returns to
normal once antidepressants are discontinued, but recently,
The serotonin reuptake inhibitor (SSRI) antidepressants
isolated reports of sustained sexual side effects persisting
are associated with an array of sexual side effects including
months or years after discontinuation of SSRI’s have sur-
diminished libido, delayed orgasm, anorgasmia, erectile dys-
faced in the literature [8,9]. In each case, depressive symp-
function or vaginal xerosis, and decreased tactile sensitivity
toms were reported to be in remission and no alternative eti-
in the genital region [1,2]. Activation of the 5-HT2A subclass
of serotonin receptors appears to account for these untoward side effects [2,3].
We present a case of persistent genital anesthesia and
diminished libido which has persisted for over one year fol-
Nefazodone is structurally and pharmacologically distinct
lowing completion of a brief course of citalopram followed
form the SSRI class and infrequently associated with sexual
side effects. Nefazodone is a potent antagonist at the post-synaptic 5-HT2A receptor site with moderate serotonin and
noradrenergic reuptake inhibition. This unique pharma-
A 32 year old woman presented with a six month history
cologic profile likely explains the low order of sexual side
of depressed mood, anhedonia, and difficulty falling asleep.
effects associated with usage [2-5]. Nefazodone has been
A prior history of depression and other psychiatric disorders
administered in conjunction with SSRIs in an effort to coun-
was absent. The patient denied diminished libido or diffi-
teract the undesirable sexual symptoms associated with the
culty achieving orgasm. No significant marital conflicts or
latter [1-3,5,6]. Alternatively, nefazodone may be substituted
other stressors were identified. Her past medical history and
for a SSRI in patients with major depression. Although ex-
physical examination were normal. Citalopram 20 mg daily
ceedingly rare, fulminate hepatotoxicity has been reported
following nefazodone administration (one case of death or liver transplant per 250,000 patients treated per year). In
Within days of beginning citalopram therapy, she noted a
fairness, physicians and consumers should be aware that
substantial decrease in libido, difficulty achieving orgasm,
drug induced liver injury (usually reversible) has been rarely
and diminished orgasmic intensity. Most distressing to the
associated with essentially all antidepressant agents .
patient was a sensation of “feeling totally numb” in her geni-
tal region with a greatly diminished capacity to respond to
clitoral and labial tactile stimulation during intercourse.
*Address correspondence to this author at the Department of Obstetrics and
Her depressive symptoms improved considerably at 4
Gynecology, Texas Tech University Health Sciences Center, School of
weeks but the sexual side effects persisted. She requested a
Medicine, 1400 Coulter Drive, Amarillo, Texas 79106 USA; Tel:
change in drug therapy rather than taking a “wait and see”
806.356.4608; Fax: 806.354.5516; E-mail: firstname.lastname@example.org
2007 Bentham Science Publishers Ltd.
2 The Open Women’ Health Journal, 2007, Volume 1
Kauffman and Murdock
approach. Nefazodone was prescribed and citalopram ta-
exposure if the condition arose initially during treatment
pered over one week. She achieved an excellent clinical re-
sponse to nefazodone 200 mg twice daily, but unfortunately,
In addition to these case reports, the emergence of an
the sexual side effects and genital anesthesia continued un-
Internet community comprised of individuals claiming per-
abated for the duration of therapy. Bupropion (on a continu-
sistent sexual dysfunction following discontinuation of vari-
ous basis) and then sildenafil (prior to intercourse) were
ous SSRI’s, albeit unsubstantiated, suggests that this phe-
added to her therapeutic regimen, but the patient failed to
nomenon may not be rare . Plainly, such an event pre-
sents a consequential quality of life issue affecting post-
Nefazodone was discontinued after 14 months, and her
depression sexual functioning with the capacity to compro-
depression remained in full remission. One year following
mise intimate relationships in men and women alike.
completion of drug therapy, she continued to complain of
Early studies of fluoxetine concluded that sexual dys-
low libido, minimal genital tactile sensation, and orgasmic
function occurred in only 2-16% of those receiving the drug,
dysfunction that was essentially unchanged from the time of
but these numbers were based primarily on patient-based
treatment. Lubrication and genital engorgement remained
voluntary reporting rather than sophisticated questionnaires
intact. The patient maintained regular, cyclic menses before,
or direct interview . In the same vein, lack of long term
follow up or failure to inquire about sustained sexual side
Neurological examination was normal. Thyrotropin, free
effects following antidepressant therapy would likely result
thyroxine, serum testosterone, sex hormone binding globu-
in underreporting of these events. Accordingly, persistence
lin, and calculated free androgen index were within normal
of orgasmic dysfunction and loss of genital tactile sensation
limits. Formal psychological consultation and testing were
following antidepressant discontinuation may be more com-
obtained, but no residual psychopathology was identified.
The mechanism of antidepressant induced sexual dys-
function is not fully understood which renders speculation on
Sexual side-effects associated with neuropsychiatric
the psychoneuroendocrinological basis of sustained post-
drugs, particularly the SSRI class, are relatively common,
treatment sexual symptoms even more challenging. Perma-
and it has been generally assumed that these annoying symp-
nent changes in serotonin transmission physiology mani-
toms abate with discontinuation of treatment. In this regard,
fested by diminished sexual behavior have been reported in
the absence of a coordinated post-treatment surveillance
murine models following neonatal or adolescent SSRI expo-
study validating this axiom is surprising.
sure [16,17], and hence, it is biologically plausible that an
SSRI related sexual side effects have ranged from 58%
analogous alteration of serotonin receptor neurophysiology
for fluoxetine to 73% for citalopram . In contrast, studies
might persist in adult humans. Bishop, et al.
of nefazodone have consistently reported a low incidence of
association between a specific 5-HT2A single nucleotide
sexual side effects [3,10,11]. In a series of 593 patients
polymorphism (SNP) and sexual side effects in a mixed gen-
treated with nefazodone from four clinical trials, abnormal
der group of individuals receiving SSRIs . This finding
orgasm was reported in only 0.2% of the participants .
raises the possibility that a specific SNP might predispose
Montejo, et al.
pinpointed sexual dysfunction in 4 of 50 de-
affected individuals to persistent post-treatment sexual dys-
pressed patients (8%) treated with nefazodone .
Although an element of impaired sexual functioning is
Persistent sexual dysfunction and genital anesthesia fol-
encountered in approximately 40-50% of depressed indi-
lowing citalopram administration has been described in one
viduals [4,12], reduced or absent genital sensation has not
other case report, but there are no published reports of these
been associated with depression or any other common psy-
symptoms following nefazodone therapy . Parenthetically,
chiatric entity . Genital anesthesia appears uniquely as-
it is entirely possible that this patient’s condition is entirely
sociated with the use of serotonergic antidepressants .
attributable to citalopram even though her length of exposure
Ordinarily, antidepressant induced sexual side effects rapidly
was only four weeks. Nevertheless, it is logical to hypothe-
diminish with termination of drug therapy [1,6], but recent
size that the unusual nefazodone-treated patient who suffers
case reports suggest that this is not always the case. Bolton,
sexual side-effects could also develop prolonged post-
described persistence of orgasmic dysfunction, genital
treatment sexual side effects similar to individuals treated
anesthesia, and diminished libido in a 26 year old male six
years following discontinuation of sertraline . Csoka and
Long term follow up will be crucial in order to determine
Shipko reported three additional cases of sustained genital
if antidepressant induced sexual dysfunction remains a per-
anesthesia and poor libido following treatment with either
manent phenomenon. Continued research into antidepressant
fluoxetine, sertraline, or citalopram . In each of these
pharmacogenomics may ultimately establish precisely who is
cases, the onset of unwanted sexual side effects first oc-
predisposed to this perplexing problem and the molecular
curred during SSRI therapy, and residual depressive symp-
basis involved. In addition, a multi-institutional long term
toms were absent at follow up. Yet another study at least
surveillance project designed to detect the true incidence of
indirectly implicated paroxetine although patients in that
persistent post-antidepressant genital anesthesia and sexual
investigation were continued on amineptine, an atypical tri-
dysfunction should be undertaken. If a positive association is
cyclic antidepressant not associated with sexual dysfunction,
found, this would have implications for pre-treatment in-
following paroxetine discontinuation . Bahrick has pro-
formed consent and could precipitate yet another “black
posed that persistent genital anesthesia and orgasmic hypo-
intensity should be considered putative markers of past SSRI
Prolonged Post-Treatment Genital Anesthesia and Sexual Dysfunction
The Open Women’ Health Journal, 2007, Volume 1 3
the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psy-chiat 2001; 62 Suppl 3: 10.
Zajecka J. Strategies for the treatment of antidepressant-related
Taylor MJ, Rudkin L, Hawton K. Strategies for managing antide-
sexual dysfunction. J Clin Psychiat 2001; 62 Suppl 3: 35.
pressant-induced sexual dysfunction: Systematic review of random-
Clayton AH, Montejo AL. Major depressive disorder, antidepres-
ised controlled trials. J Affect Disord 2005; 88: 241.
sants, and sexual dysfunction. J Clin Psychiat 2006;67 Suppl 6: 33.
Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunc-
DeVane C, Grothe D, Smith S. Pharmacology of antidepressants:
tion before antidepressant therapy in major depression. J Affect
Focus on nefazodone. J Clin Psychiat 2002; 63: 10.
Zajecka J, Dunner DL, Gelenberg AJ, et al
. Sexual function and
Bahrick A. Post SSRI sexual dysfunction. ASAP Tablet 2006; 7: 2-
satisfaction in the treatment of chronic major depression with nefa-
zodone, psychotherapy, and their combination. J Clin Psychiat
Montejo AL, Llorca G, Izquierdo JA, et al
. Sexual dysfunction
with antidepressive agents. Effect of the change to amineptine in
Augustin B, Cold J, Jann M. Venlafaxine and nefazodone two
patients with sexual dysfunction secondary to SSRI. Actas Esp
pharmacologically distinct antidepressants. Pharmacotherapy 1997;
Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C. The role of
Ferguson JM. The effects of antidepressants on sexual functioning
serotonin in sexual dysfunction: fluoxetine-associated orgasm dys-
in depressed patients: A review. J Clin Psychiat 2001; 62 Suppl 3:
Maciag D, Simpson K, Coppinger D, et al.
DeSanty KP, Amabile CM. Antidepressant-induced liver injury.
exposure has lasting effects on behavior and serotonin circuitry.
Bolton J, Sareen J, Reiss J. Genital anaesthesia persisting six years
DeJong T, Snaphaan L, Pattij T, et al
. Effects of chronic treatment
after sertraline discontinuation. J Sex Marital Ther 2006; 32: 327.
with fluvoxamine and paroxetine during adolescence on serotonin-
Csoka A, Shipko S. Persistent sexual side effects after SSRI dis-
related behavior in adult male rats. Eur Neuropsychopharmacol
continuation. Psychother Psychosom 2006; 75: 187.
Montejo AL, Llorca G, Izquierdo JA, et al.
Incidence of sexual
Bishop JR, Moline J, Ellingrod VL, et al
. Serotonin 2A -1438 G/A
dysfunction associated with antidepressant agents: A prospective
and G-protein Beta3 subunit C825T polymorphisms in patients
multicenter study of 1022 outpatients. Spanish Working Group for
with depression and SSRI-associated sexual side-effects. Neuro-psychopharmacology 2006; 31: 2281.
STUDENT ASTHMA/ANAPHYLAXIS ACTION PLAN STUDENT NAME: DATE OF BIRTH: / / (MONTH) (DAY) (YEAR) EXERCISE PRE-TREATMENT: Administer inhaler (2 inhalations) 15-30 minutes prior to exercise. (e.g., PE, recess, etc). Albuterol HFA inhaler (Proventil, Ventolin, ProAir) Use inhaler with spacer/valved holding chamber Levalbuterol (Xopenex HFA) May carry & self-admi
Heartburn, Gastroesophageal Reflux (GER), and Gastroesophageal Reflux Disease (GERD) National Digestive Diseases Information Clearinghouse What is GERD? What are the symptoms of is a more serious form of gastroesophageal U.S. Department of Health and Human Services ter (LES) opens spontaneously, for varying NATIONAL erly and stomach contents rise up into the INSTITUT